findmyKOL

Dana Rizk, MD

Enriched profile

Anupam Agarwal Endowed Professor of Medicine; Associate Dean for Clinical Trials, Heersink School of Medicine · University of Alabama at Birmingham (UAB) Heersink School of Medicine

ORCIDNPI
Region🇺🇸 Birmingham, AL · Southeast · United StatesSpecialtyNephrologyFocusChronic Kidney Disease
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Dana Rizk is Anupam Agarwal Endowed Professor of Medicine; Associate Dean for Clinical Trials, Heersink School of Medicine at University of Alabama at Birmingham (UAB) Heersink School of Medicine. OpenAlex indexes 180 publications with 4,764 citations (h-index 34); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Dana V. Rizk is Anupam Agarwal Endowed Professor of Medicine at University of Alabama at Birmingham (UAB) Heersink School of Medicine, Division of Nephrology. The public record shows 180 publications with 4,764 citations (h-index 34), centered on Chronic Kidney Disease. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 22 companies.

  • Most recent indexed publication: 2026 · Nephrology, dialysis, transplantation
  • Top research focus: Chronic Kidney Disease
  • 2 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 22 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Chronic Kidney Disease1 trialAcute Kidney Injury1 trial

Research focus

OpenAlex concept fingerprint
Chronic Kidney Disease

Drugs & molecules

across trials, industry payments and publications
Tarpeyogeneric · BudesonideClinical trialsIndustry payments10PublicationsFabhaltageneric · IptacopanClinical trialsIndustry payments7PublicationsBenlystageneric · BelimumabClinical trialsIndustry payments2Publications

Works with

trial sponsors and companies reporting payments
Otsuka Pharmaceutical Development & Commercialization, Inc.Clinical trialsIndustry payments30Travere Therapeutics, Inc.Clinical trialsIndustry payments22Novartis Pharmaceuticals CorporationClinical trialsIndustry payments13

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
180publications

Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.

4,764citations

Total citations across indexed works.

34h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials
22companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Public positions

sourced statements on record
  • Site Principal Investigator

    phase 3 APPLAUSE-IgAN trial of iptacopan (Fabhalta) in IgA nephropathy, published in NEJM

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uab.edu

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    76.2%
    Angiotensin receptor blocker (ARB)25.7%
    Losartan Potassium68%Telmisartan17%Irbesartan16%
    Part D<11 patients
    Calcium channel blocker16.1%
    Amlodipine Besylate100%
    Part D19 patients
  • Metabolism & gastrointestinal

    20.9%
    SGLT2 inhibitor14.8%
    Farxiga100%
    Part D11 patients
    Corticosteroid3.2%
    Prednisone100%
    Part D<11 patients
  • Nervous system

    2.9%
    SSRI2.9%
    Escitalopram Oxalate100%
    Part D<11 patients
Where care is delivered (Part B)60.3% facility · 39.7% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/dana-rizk-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • Other

    kdigo.org/full-kdigo-2025-igan-podcast-series-now-available

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kdigo.org
  • Other

    asn-online.org/about/bio.aspx

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asn-online.org
  • Orcid.org

    X (Twitter) handle @DanaRizk1

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →orcid.org
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asn-online.org
  • Member

    The Southern Society for Clinical Investigation

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ssciweb.org

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Director

    Clinical Trials Research, Division of Nephrology, UAB

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uab.edu
  • Medical Director

    UAB Glomerular Kidney Disease Clinic (Kirklin Clinic)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uab.edu
  • Medical Director

    Clinical Trials Administrative Office, UAB

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providerdirectory.uabmedicine.org
1 more affiliation behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.